Business Context and Reporting Period
Company: Merit Medical Systems, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2011
Business Overview: Merit designs, develops, and markets single-use medical products for interventional and diagnostic procedures. Operations are reported in two segments: Cardiovascular (cardiology and radiology) and Endoscopy (gastroenterology and pulmonology). The company completed the acquisition of BioSphere Medical, Inc. in September 2010, adding embolotherapeutic products to its portfolio.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Net Sales | $86.6 million | $67.4 million |
| Gross Profit | $39.8 million | $28.4 million |
| Gross Margin | 45.9% | 42.2% |
| Operating Income | $10.2 million | $6.3 million |
| Net Income | $6.6 million | $4.5 million |
| Diluted EPS | $0.18 | $0.13 |
| Cash from Operations | $4.6 million | $5.1 million |
| Long-Term Debt | $82.6 million | $0 (Note: Debt incurred for acquisition) |
| Cash and Equivalents | $3.5 million | $6.0 million |
| Working Capital | $77.0 million | $72.1 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 28.5% year-over-year. This was driven by a 17.4% increase in base business sales and $7.7 million in sales from the BioSphere acquisition (11.8% of total sales).
- Margin Expansion: Gross margin improved to 45.9% from 42.2%, attributed to higher-margin embolization device sales and increased direct sales in China.
- Profitability: Net income rose 47% to $6.6 million. Operating income increased 61% to $10.2 million.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose to 28.4% of sales (from 28.2%) due to support for BioSphere products. R&D expenses increased to 5.8% of sales (from 4.5%) due to the addition of the BioSphere R&D group and new product development.
- Debt and Interest: Interest expense increased significantly to $425,000 (from $35,000) due to long-term debt incurred for the BioSphere acquisition. The company currently has $82.6 million outstanding on a $125 million credit facility.
- Tax Rate: The effective tax rate increased to 32.2% from 28.8%, primarily due to higher profitability in U.S. operations taxed at higher rates than foreign operations.
Guidance, Outlook, and Risks
- Outlook: Management expects continued growth in geographic regions and product groups. The company plans to expand product offerings in strategic foreign markets using a direct sales approach.
- Capital Expenditures: The company plans to construct two new production facilities (South Jordan, Utah, and Galway, Ireland) and a parking terrace with total anticipated costs of $52 million. Approximately $11.8 million has been incurred to date.
- Liquidity: Management believes existing cash, anticipated cash flows, and available credit ($42.4 million remaining on the credit facility) are adequate to fund operations for the next 12 months.
- Risks: Key risks include product recalls, liability claims, regulatory changes (FDA 510(k) process), reimbursement policy changes, foreign currency fluctuations (Euro, GBP, CNY), and the successful integration of the BioSphere acquisition.
- Subsequent Event: A 5-for-4 forward stock split was authorized and completed on May 5, 2011. All share and EPS data in the filing have been adjusted to reflect this split.
Investor Verification Checklist
- Acquisition Integration: Verify the commercialization progress and sales contribution of BioSphere embolization devices beyond the initial quarter.
- Debt Covenants: Confirm continued compliance with leverage and EBITDA ratios under the $125 million Credit Agreement.
- Capital Projects: Monitor the timeline and cost overruns for the planned $52 million in new facility construction.
- Foreign Currency Exposure: Assess the impact of Euro and GBP fluctuations on the 14.1% of sales denominated in foreign currencies.
- Endoscopy Segment: Review the path to profitability for the Endoscopy segment, which reported an operating loss of $978,000 for the quarter.